Dong Xu

TL;DR: Long‐term monitoring showed low rates of resistance in nucleoside‐naïve patients during 5 years of ETV therapy, corresponding with potent viral suppression and a high genetic barrier to resistance, support ETV as a primary therapy that enables prolonged treatment with potentiral suppression and minimal resistance.

TL;DR: Lambda was associated with improved or similar rates of virologic response with fewer extrahepatic adverse events than alfa in chronic HCV infection in patients chronically infected with HCV genotypes 1-4.

TL;DR: On-treatment, lambda showed greater early effects on HBV-DNA and qHBsAg, and comparable serologic/virologic responses at end-of-treatment; however, post- treatment, alfa-associated HBeAg seroconversion rates were higher, and key secondary results mostly favored alfa.

TL;DR: This retrospective analysis demonstrated that HBeAg‐negative CHB patients treated with entecavir responded similarly irrespective of baseline ALT level, however, H beAg‐positive patients with mildly elevated ALT responded less well to treatment with entECavir than did those with ALT greater than 2 × ULN.